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AbstrAct
background and aims To assess whether aspartate 
aminotransferase (AST), alanine aminotransferase (ALT) 
and alkaline phosphatase (AP) levels can predict the 
diagnosis of primary biliary cholangitis (PBC) or any other 
diagnoses and whether PBC occurs either simultaneously 
or independently of other liver diseases among 
antimitochondrial antibody (AMA)-positive patients.
Methods Demographic and clinical variables were 
assessed in 90 AMA-positive patients with and without 
liver biopsies. These patients were further categorised 
as having a diagnosis of PBC, overlap syndrome or ‘not 
established with a diagnosis of PBC’. Receiver operating 
characteristic curves were constructed to determine 
the thresholds of liver enzymes that predict these three 
diagnoses.
results The 48 patients with liver biopsies were more 
frequently female and had significantly higher AP levels 
compared with the non-liver biopsy group. Based on liver 
biopsy findings, 12, 12 and 22 patients were assigned 
a diagnosis of PBC, overlap syndrome with autoimmune 
hepatitis and PBC and ‘not established diagnosis of PBC’, 
respectively. Seven of 12 patients classified as PBC had AP 
level of ˂200 IU. AST, ALT and AP levels were significant 
predictors of a diagnosis of overlap syndrome compared 
with the rest of the patients; however, these tests were 
not discriminatory between diagnoses of PBC and ‘not 
established with PBC’. Findings of fatty liver and bile duct 
injury on liver biopsies were not significantly associated 
with any liver test pattern.
conclusions As the liver test pattern did not correlate 
with the liver biopsy findings of PBC or other non-
PBC diagnoses in AMA-positive patients at risk for 
other disease, a liver biopsy and/or non-invasive liver 
assessment along with serum liver tests should be 
interpreted to complete liver evaluation.
IntroductIon
Antimitochondrial antibody (AMA) is 
diagnostic of primary biliary cholangitis 
(PBC) if an elevated alkaline phosphatase 
(AP) level or a compatible liver histology is 
documented on clinical evaluation. More-
over, among AMA-positive individuals, a 
combination of high AP and low aspartate 
aminotransferase (AST) has an excellent 
positive predictive value for the diagnosis of 
PBC alone, eliminating the need for a liver 
biopsy.1 In contrast, a liver biopsy has been 
reported to be diagnostic for PBC among 
those who have normal liver tests including 
AP in AMA-positive patients.2 Despite being 
an option for establishing the diagnosis of 
PBC and occasional reports of biopsy-proven 
PBC with and without cirrhosis in AMA-pos-
itive patients with normal liver tests,3 a liver 
biopsy can miss the histological changes of 
PBC.1 4 5 Other liver diseases such as nonal-
coholic fatty liver disease (NAFLD), autoim-
mune hepatitis (AIH) and viral hepatitis can 
simultaneously occur with PBC in AMA-posi-
tive patients.6 7 Although the overlap of PBC 
with AIH has been extensively studied, clear 
diagnostic and management criteria remain 
suboptimal, leaving the ultimate diagnosis to 
the clinical judgement of a physician based 
on histology.8
As AMA testing has become widely avail-
able for liver disease evaluation, the inci-
dence of PBC that is diagnosed based on 
AMA positivity and high AP without liver 
biopsy has been increasing.9 Many patients 
test positive for AMA when laboratory tests 
are ordered to work up the aetiology of their 
liver disease, regardless of the presence of 
the ‘typical liver test pattern’ described in 
association with PBC. These AMA-positive 
patients can be diagnosed or remain undiag-
nosed with PBC or may have no liver disease 
or risk of PBC, particularly as liver biopsies 
are not done on many patients with a low 
AP level or near normal liver tests.5 This 
approach stands in contrast to reported data 
in the literature where a liver biopsy is indi-
cated for a lower or normal AP rather than 
just a higher AP level.1
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In our hepatology practice at Maricopa Integrated 
Health Centre (MIHS), a safety-net hospital in Phoenix, 
Arizona, AMA has been included in the battery of liver 
tests that are used for liver disease evaluation. We have 
encountered patients with a positive AMA who exhibited 
a variety of patterns of liver tests who eventually were 
found to have other liver diseases present besides PBC 
and/or in whom a diagnosis of PBC could not be estab-
lished. We sought to assess the clinical characteristics and 
differences among AMA-positive patients with or without 
a liver biopsy. Furthermore, we analysed AMA-positive 
patients with liver biopsies to find any particular liver tests 
that could reliably differentiate liver pathology features 




Maricopa Medical Centre (MMC) is a state-owned 
hospital that fulfils primary healthcare needs of patients 
who are insured by the state or are uninsured. The hepa-
tology clinic receives consults from MMC’s emergency 
department, hospital discharges and family health clinics 
owned by MIHS with only occasional consults received 
from community gastroenterologists.
data collection
Electronic medical records (EMRs) at MIHS in Phoenix, 
Arizona, were accessed to review patient records for this 
retrospective study approved by the institutional review 
board. Data including demographics, weight, alcohol/
drug abuse, diabetes mellitus (DM), liver imaging 
(ascites, varices, fatty liver), liver tests, antinuclear anti-
body (ANA) and F-actin antibodies, upper gastroin-
testinal endoscopy (EGD) findings (varices) and liver 
biopsy results were collected. The highest available values 
(in one collection) among all the documented levels of 
AP, total bilirubin, alanine aminotransferase (ALT) and 
AST before initiation of ursodeoxycholic acid (URSO) 
therapy were recorded; the lowest level of serum albumin 
was also recorded.
Laboratory and clinical methods
The semiquantitative detection of mitochondrial anti-
bodies was conducted using the QUANTA Lite M2 EP 
(MIT three antigen) ELISA with a cut-off value of 25 
determined to be positive for AMA. The sensitivity and 
specificity for this test has been reported as 87.3% and 
98.7%, respectively.10 11 F-actin antibody and ANA were 
reported positive if the values were above 19 units and 
above 1:40, respectively. Ascites or esophageal varices 
were marked present if documented on imaging, EGD 
reports or provider notes.
Interpretation of liver biopsy and other diagnostic tests
Variables including bile duct injury, fatty change, fibrosis, 
cirrhosis and nonalcoholic steatohepatitis (NASH)were 
extracted from liver biopsy reports. Thirty-six of 48 biop-
sies were read by one of the five pathologists at MIHS. For 
23 patients, biopsies were sent out for a second opinion 
from an expert hepato-pathologist. A diagnosis of overlap 
syndrome of AIH and PBC was determined based on the 
Paris criteria.12 Those patients who had bile duct injury 
on the liver biopsy and did not fulfil Paris criteria for the 
overlap syndrome were classified as PBC. Patients who 
didn’t fulfil Paris criteria or had no evidence of bile duct 
injury on the liver biopsy were labelled as ‘not established 
with PBC’.
Bile duct injury was reported if there were inflam-
matory cells within the bile duct lining epithelium or 
lumen or evidence of degeneration of bile duct lining 
cells. If typical changes of PBC including bile duct gran-
ulomas were not present and only bile duct injury was 
documented on a liver biopsy, the patient was classified 
as having a diagnosis compatible with PBC. Liver biop-
sies of six patients were also stained with cytokeratin-7 
(CK-7) and/or cytokeratin-19 (CK-19) to highlight 
Canals of Hering (CoH); however, absence or paucity of 
summary box
What is already known about this patient population?
 ► Primary biliary cholangitis (PBC) can occur at any level of alkaline 
phosphatase (AP).
 ► At a higher level of AP, PBC can be diagnosed without a liver 
biopsy provided that the antimitochondrial antibody (AMA) is 
positive.
 ► Patients with high AP and high aspartate aminotransferase (AST) 
levels should undergo a liver biopsy to diagnose the overlap of 
autoimmune hepatitis with PBC.
 ► Liver biopsy and/or non-invasive tests should be considered in 
AMA-positive patients with lower AP levels to identify patients at 
risk for fatty liver.
What are the new findings?
 ► In a community practice, liver biopsies are more likely to be 
performed in patients with higher rather than lower AP levels 
among AMA-positive patients.
 ► Compared with a tertiary centre, a diagnosis of PBC can be 
documented at a lower AP level in a community practice.
 ► The yield of a liver biopsy for the diagnosis of PBC in patients 
with a positive AMA and a lower AP level is substantial; the use of 
cytokeratin-19 or cytokeratin-7 stains can further highlight early 
changes of PBC on a liver biopsy.
 ► Despite undergoing a liver biopsy, many AMA-positive patients 
would not be diagnosed with PBC and other diseases such as 
nonalcoholic fatty liver disease (NAFLD) could be documented.
How might it impact on clinical practice in the foreseeable 
future?
 ► A liver biopsy should be considered in AMA-positive patients 
with a lower AP regardless of AST level where the diagnosis of 
PBC cannot be established with liver tests alone or there exists 
the possibility of another liver disease. Moreover, among those 
AMA-positive patients with higher AP and lower AST levels where 
liver tests alone can make the diagnosis of PBC, a liver biopsy may 
find additional or alternate diagnoses. Non-invasive tests or a liver 
biopsy could be considered to evaluate other underlying diseases 
such as NAFLD that can be concomitantly present along with PBC.
 3Tan S, et al. BMJ Open Gastro 2017;4:e000158. doi:10.1136/bmjgast-2017-000158
Open Access
CoH was not used as a criterion to label the diagnosis of 
PBC. NASH was described if there was fibrosis or hepa-
tocellular drop out along with at least a 5% fatty change 
present on the liver biopsy. NAFLD was diagnosed in a 
patient with evidence of hepatic steatosis on either liver 
biopsy and/or imaging.13 AST to Platelet Ratio Index 
(APRI) and Fibrosis-4 (FIB-4) were calculated using stan-
dard equations.14 15 An AST level of 30 and 20 IU for 
men and women, respectively, were used for APRI score 
calculation.16
A diagnosis of DM was ascertained if it was documented 
in the EMR or if the haemoglobin A1C level was ≥6.5. 
A diagnosis of alcoholic liver disease was given if docu-
mentation of alcohol abuse without any other aetiology 
of liver disease was documented in the EMR except the 
possible diagnosis of PBC with a positive AMA. Criteria 
set by the International Autoimmune Hepatitis Group 
was used to make a diagnosis of AIH.17
statistical analysis
All statistical analyses were conducted using SPSS 21. 
Continuous variables were assessed using Kruskal-Wallis 
and Mann-Whitney tests and categorical variables by 
using Fisher’s 2-sided exact tests. Receiver operating 
characteristic curves (ROCs) were created to determine 
the optimal cut-off levels (least misclassification) of AP, 
AST and ALT to determine a correct diagnosis of PBC or 
overlap syndrome and of patients who could not be estab-
lished with a diagnosis of PBC. The area under the ROC 
for liver enzymes (AP, ALT and AST) in predicting the 
diagnosis of overlap, PBC and non-established with PBC 
based on liver biopsies were reported. We also reported 
the recommended liver enzyme thresholds for optimum 
sensitivity and specificity (least misclassification) of the 
liver disease diagnoses based on ROCs.
resuLts
We identified 90 AMA-positive patients, 48 with liver 
biopsies, from January 2012 to September 2015. Data on 
46 of 48 patients with liver biopsies were collected before 
initiation of URSO therapy. Two patients had liver biop-
sies performed at an outside facility, and since data and 
histology prior to URSO initiation was not available, they 
were excluded from the final statistical analysis of the 
liver biopsy group.
Liver biopsy versus no liver biopsy groups
The median APRI and FIB-4 scores for all 90 patients 
were 1.71 and 1.96, respectively (table 1). As APRI and 
FIB-4 were designed for patients with only a moderate 
degree of AST/ALT elevation and a moderate reduction 
of platelet count,14 15 we excluded patients with AST˃200 
IU/L and/or ALT level of ˃200 IU/L and/or platelet 
count of ˂20 000 cc/mm3. The mean (median, range) 
APRI for 30 patients who underwent a liver biopsy was 
2.4 (1.5, 0.5–8.9) compared with 1.5 (0.9, 0.2–7.1) for 36 
patients without a liver biopsy (p=0.057). Mean (median, 
range) FIB-4 was 3.3 (2.0, 0.7–14.2) for liver biopsy 
patients and 2.7 (1.4, 0.5–17.88) for non-biopsy patients 
(p=0.046). The corresponding author reviewed data on 
patients without liver biopsies and assigned a diagnosis 
of PBC to eight patients with a mean AP level of 455 IU 
(range 196–492). None of the patients in the no liver 
biopsy group had a suspected overlap syndrome. The 
number of females and AP level was significantly higher 
in the liver biopsy group (n=48) compared with the 
no liver biopsy group (n=42). Mean levels of AST, ALT 
and total bilirubin were numerically higher and serum 
albumin lower in the liver biopsy group compared with 
those who did not have liver biopsies, but the differences 
were not statistically significant.
Grouping of subjects based on liver biopsy findings
Based on liver biopsy findings and Paris criteria, a diag-
nosis of PBC, overlap syndrome and ‘not established with 
PBC’ were assigned to 12, 12 and 22 patients, respec-
tively. Twenty-six of 90 patients were on URSO therapy 
at the time of data collection. Of these 26 patients, 22 
had liver biopsies. Additional data were collected on all 
except two patients prior to URSO exposure to allow 
baseline pretherapy information to be used in our statis-
tical calculations. These two patients showed liver biopsy 
changes compatible with and diagnostic of PBC and were 
not analysed in the final data set. Table 2 summarises 
epidemiological, liver biopsy and other clinical variables. 
Four of six patients whose liver biopsies were stained with 
CK-7 or/and CK-19 showed paucity or absence of CoH 
in the peri-portal zone; however, there was no correla-
tion between level of AP, presence or absence of bile 
duct injury on H&E stain and paucity or absence of CoH. 
Three patients with paucity of CoH highlighted on CK-7 
and/or CK-19 staining didn’t show any evidence of bile 
duct injury on H&E.
Patients with overlap syndrome
All 12 patients diagnosed with overlap syndrome showed 
some bile duct injury. Only one patient diagnosed with 
overlap syndrome did not have hepatitis but fulfilled 
the Paris criteria. Average mean, median and range of 
IgG, IgM and IgA levels were available from 10 overlap 
patients: IgG: mean, 1906 mg/dL; median, 1753 mg/dL; 
range 928–3030 mg/dL; IgM: mean, 642 mg/dL; median, 
451 mg/dL; range 105–3000 mg/dL; and IgA: mean, 
337 mg/dL; median, 292 mg/dL; range, 142–602 mg/dL. 
Cirrhosis and markers of portal hypertension including 
ascites and varices were seen more frequently among 
patients with overlap diagnosis, but the differences were 
not statistically significant.
All patients with hepatitis C and/or hepatitis B were 
included in the ‘not established with PBC’ group. Eight 
patients had both bile duct injury consistent with PBC 
and fatty change consistent with NAFLD documented 
on their liver biopsies. One patient who was categorised 
as NAFLD based on the initial liver biopsy underwent a 
second biopsy 10 years later (after data collection) and 
showed severe ductopenia and confirmed changes of 
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Table 1 Characteristics of AMA-positive patients with or without a liver biopsy
Features Liver biopsy (n=48) No liver biopsy (n=42) p Value
Hispanic/non-Hispanic (%) 32/16 (66.7) 28/14 (66.7) >0.999
Sex: female (%) 42/6 (87.5) 23/19 (54.8) 0.001
Alcohol (%) 14/34 (29.2) 18/24 (42.9) 0.193
Substance abuse (%) 12/36 (25.0) 10/32 (23.8) >0.999
Overweight or obese (%) 40/8 (83.3) 32/10 (76.2) 0.438
DM (%) 11/36 (23.4) 10/31 (24.4) >0.999
Age mean (median, range) 52 (54, 14–77) 54 (55, 25–79) 0.533
Laboratory
  Platelet count 150−450×109/L 232 (225, 53–619) 203 (205, 7–417) 0.449
  Albumin, mean (median, range) (g/dL) 3.6 (3.9, 1.9–4.9) 3.9 (4.1, 2.5–5.1) 0.070
  ALT, mean (median, range) (IU/L) 153 (69, 15–1540) 102 (72, 8–311) 0.958
  AST, mean (median, range) (IU/L) 144 (81, 19–960) 100 (64, 12–516) 0.271
  AP, mean (median, range) (IU/LT)







  APRI mean (median, range) 4.728 (2.292, 0.478–41.611) 5.399 (1.338, 0.210–121.429) 0.075
FIB-4 mean (median, range) 4.138 (2.116, 0.721–25.494) 7.347 (1.683, 0.497–167.571) 0.176
  ANA (%) 14/31 (31.1) 12/25 (32.4) >0.999
  F-actin Y (%) 19/26 (42.2) 9/24 (27.3) 0.234
  HCV (%) 8/40 (16.7) 9/33 (21.4) 0.379
  HBV (%) 1/47 (2.1) 1/41 (2.4) >0.999
  Imaging
   Steatosis (%) 14/28 (33.3) 11/24 (31.4) >0.999
   Varices Y/N, (%) 9/36 (20) 7/30 (18.9) >0.999
   Ascites (%) 7/39 (15.2) 7/35 (16.7) >0.999
Therapy
  URSO (%) 22/26 (45.8) 4/38 (9.5) <0.001
ALT, alanine aminotransferase; ANA, antinuclear antibody; AP, alkaline phosphatase; APRI, AST to Platelet Ratio Index; AST, aspartate 
aminotransferase; DM, diabetes mellitus; FIB-4, Fibrosis-4; HBV, hepatitis B virus; HCV, hepatitis C virus; URSO, ursodeoxycholic acid.
PBC. While the first liver biopsy showed a normal number 
of expected CoH and steatohepatitis, the second liver 
biopsy showed complete absence of CoH, ductopenia, 
stage IV PBC and a lesser degree of steatohepatitis. AP 
levels of this patient trended up over time but remained 
under 200 IU throughout the illness course.
Table 3 summarises the differences in liver tests 
between three groups of patients with liver biopsies. 
AST, ALT, AP and total bilirubin values were significantly 
higher in overlap syndrome compared with ‘non-estab-
lished with PBC’ and PBC groups. Patients categorised as 
PBC had the lowest AST and ALT values, but there was no 
significant difference compared with the non-established 
with PBC group. The mean AP levels were numerically 
lower and AST/ALT levels were numerically higher in 
the non-established with PBC group compared with the 
PBC group, but the differences did not achieve statistical 
significance. Seven patients with a diagnosis of PBC had 
an AP level of ˂200 IU.
A non-parametric ROC plot of AP for distinguishing 
between overlap (n=12) and non-overlap (n=34) 
diagnoses among AMA patients with liver biopsy results 
showed an area under the curve of 0.853 (p<0.001, 
figure 1). The cut-off/threshold for AP to achieve the 
optimum sensitivity and specificity (least misclassifi-
cation) of overlap versus non-overlap diagnosis was at 
485 IU. Similarly, the ideal ALT cut-off was 75.5 for the 
diagnosis of overlap (AUC=0.750, SE=0.833, Sp=0.735, 
p=0.11) and the best AST cut-off was determined to 
be 86.5 (AUC=0.830, SE=0.917, Sp=0.706, p=0.001). 
ROC-determined liver enzyme cut-offs to differentiate 
between PBC and not-established PBC were not discrim-
inatory for AP (AUC=0.563, p=0.556), ALT (AUC=0.449, 
p=0.632) and AST (AUC=0.354, p=0.173).
dIscussIon
In our study of AMA-positive patients, with or without 
liver biopsies, only 22% (12 with and 8 without a liver 
biopsy; 20/90) could be diagnosed with PBC alone. Other 
diseases were frequently seen in this cohort including 
overlap syndrome of PBC with AIH, as well as NAFLD, 
alcoholic liver disease and hepatitis C virus infection. 
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Table 3 Laboratory features of liver biopsy group (n=46)
Laboratory features Non-established PBC (n=22) Overlap (n=12) PBC (n=12) p*
ALT mean (median, range) IU/L 115 (62, 15–554) 332 (186, 24–1540) 65 (64, 27–133) 0.037†‡
AST mean (median, range) IU/L 121 (70, 19–720) 287 (185, 29–960) 57 (54, 29–85) 0.002†‡
AP mean (median, range) IU/L 185 (160, 72–428) 638 (688, 94–1357) 244 (180, 93–679) 0.001†‡
Total bilirubin mean (median, range) 2.136 (0.95, 0.2–13.5) 5.05 (4.25, 0.6–19.5) 0.692 (0.55, 0.2–1.9) 0.001†‡
Platelet count mean ×109 (median, 
range)
214 (199,53–523) 311(189, 60-443) 255 (245, 72–598) 0.397
Albumin mean (median, range) 3.8 (4, 1.9–4.9) 3.4 (3.5, 2.2–4.3) 3.8 (3.9, 2.6–4.3) 0.244
*Independent sample Kruskal-Wallis test.
†Mann-Whitney test significant for non-established PBC versus overlap.
‡Mann-Whitney test significant for overlap versus PBC.
§Mann-Whitney test significant for Non-established PBC versus PBC.
ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; PBC, primary biliary cholangitis.
Table 2 Clinical and liver biopsy features of liver biopsy group (n=46)
Patient features Non-established PBC (n=22) Overlap: Paris (n=12) PBC (n=12) Fisher’s exact P*†‡
Age, mean (median, range) 52 (54, 25–76) 50 (55, 14–752) 48 (50, 27–64) 0.717§
Sex: female 18 (81.8%) 10 (83.3%) 12 (100%) 0.389
Substance abuse 9 (40.9%) 1 (8.3%) 2 (16.7%) 0.103
Alcohol use 9 (40.9%) 3 (25.0%) 1 (8.3%) 0.121
Overweight/obese 20 (90.9%) 9 (75.0%) 10 (83.3%) 0.435
DM¶ 5 (23.8%) 1 (8.3%) 5 (41.7%) 0.175
Biopsy
  BDI 0 12 (100%) 12 (100%) <0.001*‡
  Fatty change 12 (54.5%) 2 (16.7%) 5 (41.7%) 0.110
  Fibrosis 9 (64.3%) 4 (66.7%) 5 (50.0%) 0.728
  Cirrhosis 8 (61.5%) 6 (75.0%) 2 (25.6%) 0.176
  Cholestasis 1 (4.5%) 5 (41.7%) 2 (16.7%) 0.016*
  NASH 8 (36.4%) 2 (16.7%) 3 (25.0%) 0.586
  Piece meal necrosis 4 (18.2%) 11 (91.7%) 1 (8.3%) <0.001*†
Imaging
  Ascites¶ 3 (13.6%) 4/11 (36.4) 0/11 (0%) 0.068
  Varices¶ 4/21 (19.05) 4 (33.35) 1/10 (10%) 0.449
  Steatosis¶ 7/20 (35.0%) 3/9 (33.3%) 4/11 (36.4%) >0.999
Serologies
  Hepatitis C 8 (36.4%) 0 0 –
  Hepatitis B 1 (4.5%) 0 0 –
  ANA 2 (9.5%) 8 (72.7%) 4 (36.4%) 0.001*†‡
  F-actin 5 (26.3%) 9 (75%) 4 (33.3%) 0.025*
*Fisher’s exact text significant for non-established PBC versus overlap.
†Fisher’s exact test significant for overlap versus PBC-Paris.
‡Fisher’s exact test significant for non-established PBC versus PBC-Paris.
§Independent samples median test comparing age across three groups.
¶n less than the n presented at the header.
ANA, antinuclear antibody;  BDI, bile duct injury; DM, diabetes mellitus; PBC, primary biliary cholangitis.
We found that more females and higher AP level, APRI 
and FIB-4 scores were associated with ordering a liver 
biopsy. However, we did not find any correlation between 
AP, AST and ALT levels and liver biopsy findings that 
would support a diagnosis of PBC. Our data corroborate 
previous reports and guidelines that a liver biopsy should 
be considered when high AP and AST levels are docu-
mented in AMA-positive patients in order to differentiate 
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Figure 1 Non-parametric receiver operating characteristic curve plot of three liver enzymes in distinguishing between 
overlap versus other diagnoses (grey shaded, (a–c) and PBC versus not established PBC (d–f) in AMA-positive patients from 
a community hepatology practice. ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminotransferase; 
PBC, primary biliary cholangitis.
PBC from the overlap of PBC and AIH, particularly as the 
medical therapy for these two conditions is different.1 18
As a community hospital taking care of a predomi-
nantly Hispanic patient population, we evaluated many 
patients with non-specific elevation of liver tests with a 
battery of liver serological tests including AMA. The 
work up of abnormal liver tests in the community setting 
is not standardised and is based on the expert opinion 
of the healthcare provider and the expected clinical 
profile of an individual patient. There are no standard 
published guidelines regarding the use of AMA as part of 
the routine work up of patients with abnormal liver tests 
or NAFLD. The complete clinical assessment of patients 
with a positive AMA and the use of the liver biopsy to 
either diagnose or stage PBC is now focused on the possi-
bility of other liver disease(s) being present in the indi-
vidual patient.1 2 19–21
Data reported in the literature have shown a variety 
of outcomes of AMA-positive patients depending on 
the circumstances in which AMA was ordered. Among 
‘healthy’ people and blood donors, 0.07%–9.9% test 
positive for AMA.22 23 Only 0.73% of AMA-positive Japa-
nese patients from these settings were reported to have 
symptomatic PBC.24 Most recently, a French study reported 
that, among 720 AMA-positive patients, the prevalence of 
patients without evidence of PBC was 16.1 per 100 000; 
moreover, among these patients, 16% of those with no 
evidence of cirrhosis and a normal ALP progressed to 
PBC over 5 years.5 Metcalf et al described the follow-up 
of 29 asymptomatic patients who were AMA positive and 
had normal AP levels and no signs of liver disease at first 
detection. All 29 patients were previously screened in a 
work up for another autoimmune disease. Initial work up 
on these patients showed their AP levels to be ˂92 IU and 
24 of 29 patients showed histological changes ‘consistent’ 
or ‘compatible’ with PBC. Ten years later, the majority 
of these patients showed liver enzyme abnormalities 
including an elevated AP, and four of nine liver biopsies 
showed progression of liver injury.2 21
Data from a tertiary hospital that used 240 IU as the 
upper limits of normal (ULN) for AP in their own cohort 
of patients (all with liver biopsies) convincingly docu-
mented that an AP level of ≥1.5× ULN and AST of ˂5× 
ULN had a 98.5% positive predictive value for the diag-
nosis of PBC. However, in contrast to our data where the 
AP level was much lower and the majority of AMA-positive 
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patients could not be diagnosed with PBC, only 25/156 
patients in their study were diagnosed with diseases other 
than PBC. Nine patients were diagnosed with an overlap 
of AIH and PBC; these patients were categorised sepa-
rately from the PBC patients and curiously had signifi-
cantly lower AP levels compared with the PBC group. 
All patients had liver biopsies, and an AP level of 526 IU 
was documented to have 95% sensitivity for histological 
correlation with a diagnosis of PBC. The researchers 
concluded that a liver biopsy is not necessary for the diag-
nosis of PBC in patients with a high AP and low AST but 
should be considered in those who have high AST and 
high AP levels to diagnose overlap syndrome; however, 
the evaluation of patients with low AP and low AST levels 
was not discussed.1 The differences in laboratory data 
between our primary care practice and data reported 
from this tertiary centre reflect the patient referral trends 
in these two hospital systems.
Changes of fatty liver either on imaging or liver biop-
sies were randomly present in our patients without any 
association to any distinct pattern of liver enzymes. 
NAFLD has been reported to occur among patients with 
normal liver enzymes, and many are diagnosed with 
liver disease based on imaging studies.25 Up to 57% of 
patients with PBC have been reported to have NAFLD 
with metabolic syndrome documented in some. More-
over, a combination of obesity, fatty liver and PBC has a 
worse liver clinical outcome compared with PBC alone.6 
The prevalence of AMA has been reported to be 2.38% 
in NAFLD,26 5%–35% in AIH27 28 and 8% among patients 
with chronic hepatitis C (CHC).7 It has been reported 
that patients with NAFLD with positive NOSA (non-or-
gan-specific antibodies) do not have worse liver disease 
outcomes.29 In another report, 33% of patients with CHC 
who were positive for AMA showed more than twofold 
elevation of AP and 22% had a histological pattern 
compatible with PBC.7 None of our eight AMA-positive 
patients with CHC who had a liver biopsy showed any 
changes of PBC; however, nine patients with CHC who 
did not undergo a liver biopsy could have had an overlap 
of CHC with PBC. We believe that our finding of several 
patients with an overlap of PBC with AIH and NAFLD 
could be partly attributed to a predilection for these 
diseases in the Hispanic population.30 31
While the odds of making a correct diagnosis of PBC are 
high among AMA-positive patients with high AP levels,1 
those with lower AP values21 could be missed with early 
PBC or advanced liver disease without the performance of 
a liver biopsy.3 32 In our practice, patients with lower liver 
enzymes and appearance of fatty liver and/or hepatic 
decompensation on imaging studies did not undergo 
liver biopsy (table 1). Our data corroborate the findings 
of a recent report that documented that AMA-positive 
patients with normal AP and less liver disease typically do 
not undergo a liver biopsy5 and support that the yield of 
liver biopsy for the diagnosis of PBC or other diagnoses is 
in fact substantial in these particular patients. AMA-pos-
itive patients with a normal or near normal AP who did 
not undergo a liver biopsy are labelled ‘non-established 
with PBC’ or, if they have undergone a liver biopsy and 
show subtle changes of PBC yet do not fulfil histological 
criteria, are categorised as ‘compatible’ with PBC. Such 
patients have been shown to be at risk for progression to 
overt PBC.2 5 We found loss of CoH on a liver biopsy to be 
a useful predictor of early PBC; however, we also found 
a patient who had bile duct injury on H&E stain, but no 
evidence of loss of CoH on K-19, highlighting that while 
loss of CoH can be a harbinger of early PBC,4 this finding 
may not be consistently present in early PBC.
PBC can adversely affect the quality of life even in its 
early stages, and a higher mortality not related to liver 
disease has also been reported for patients with PBC, thus 
justifying a full work up in all AMA-positive patients.5 33 
Moreover, it is becoming clear that some AMA-positive 
patients would have changes of PBC and/or NAFLD 
regardless of the pattern or degree of elevation of liver 
enzymes. As the treatment of PBC differs from NAFLD or 
alcoholic liver disease, the documentation of both diag-
noses in a patient will help a clinician to come up with a 
comprehensive management plan for each AMA-positive 
patient.
As many patients with a positive AMA do not have PBC 
at the time of AMA testing, some might argue that there 
is no need to order a test that can lead to further work 
up, costs and patient anxiety and thus potentially avoid 
a liver biopsy with its inherent risks.1 It is, of course, 
important to remember and discuss with patients that a 
liver biopsy is an invasive procedure that has high cost, 
is limited by sampling error and observer variability and 
has risk, although limited, for serious procedure-re-
lated complications.34 35 Fortunately, there have been 
multiple advances in recent years for non-invasive liver 
disease evaluation, including particularly MRI proton 
density fat fraction and MR elastography for quantifica-
tion of steatosis and fibrosis36 and elastographic methods 
for assessing fibrosis, including FibroScan (Echosens; 
Paris, France)37 38 and real-time 2-D shear wave elas-
tography done with the SuperSonic Imagine Real-time 
ShearWave Elastography ultrasound system (Aixplorer, 
Aix-en-Provence, France).39–41 The addition of the 
Controlled Attenuation Parameter software for use with 
the FibroScan system has also made accurate assessment 
of steatosis possible with this elastographic system,42–44 
with the XL probe improving the accuracy of liver stiff-
ness measurement in obese patients.45 The availability of 
these new modalities for liver disease evaluation may give 
us the opportunity to perform a thorough non-invasive 
analysis of AMA-positive patients, eliminating for at least 
some patients the need for a liver biopsy.
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